GLP-1-S

Categories:

GLP-1-S is a research-use-only peptide under investigation for its potential pharmacological properties in controlled laboratory settings. This compound is intended for academic and research applications, including in vitro and in vivo studies. It is not approved for human or veterinary use and is for exclusive laboratory-use context only.

Price range: $69.00 through $89.00

⚠️ RESEARCH USE ONLY

This product is for R&D purposes only and is not approved for human or veterinary use.

GLP-1-S: A Research-Use-Only Peptide for Exploratory Investigations

GLP-1-S is a synthetic analog of glucagon-like peptide-1 (GLP-1), designed for use in academic and industrial research environments. This peptide is a critical tool for studying the mechanisms of GLP-1 receptor signaling, which has implications in metabolic regulation, neuroendocrine research, and potential drug discovery projects. GLP-1-S is provided in a research-grade formulation intended for controlled laboratory use only.

Research Context

Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose homeostasis, appetite regulation, and gastrointestinal motility. Naturally produced in the gut, GLP-1 binds to GLP-1 receptors to modulate insulin secretion, suppress glucagon release, and promote satiety. Synthetic analogs, such as GLP-1-S, offer enhanced stability and receptor affinity, enabling precise experimental manipulations in preclinical models.

Research Overview

GLP-1-S is utilized in basic science research to investigate the pharmacology of GLP-1 receptor agonists, including their effects on energy balance, neuroendocrine signaling, and metabolic diseases. Researchers employ this peptide to study receptor binding kinetics, pharmacokinetics, and potential therapeutic applications in conditions like diabetes or obesity. Given its role in counteracting insulin resistance, GLP-1-S serves as a valuable probe for exploring novel treatments in controlled experimental settings.

Key Research Focus Areas

  • Neuroendocrine Signaling: Investigating GLP-1’s role in hypothalamic and brainstem circuits, particularly in appetite regulation and metabolic feedback mechanisms.
  • Metabolic Pathways: Assessing GLP-1-S’s impact on glucose tolerance, insulin sensitivity, and adipocyte function in preclinical models.
  • Pharmacokinetics and Stability: Analyzing the peptide’s half-life, receptor binding affinity, and metabolic clearance to optimize analog design for therapeutic development.
  • Cross-Species Comparisons: Evaluating GLP-1-S’s efficacy in rodent, non-human primate, or other model systems to translate findings into potential clinical applications.

Research Compliance and Safety

This peptide is provided solely for research purposes under the supervision of qualified professionals in accredited institutions. Users must adhere to all applicable local, national, and international regulations governing research chemicals, including proper documentation, inventory control, and disposal protocols. GLP-1-S is not intended for human or animal therapeutic use and should not be administered outside a controlled experimental framework.

For research use only. Not for human or animal consumption.

Size

10MG, 20MG

Reviews

There are no reviews yet.

Be the first to review “GLP-1-S”

Your email address will not be published. Required fields are marked *

GLP-1-S: A Research-Use-Only Peptide for Exploratory Investigations

GLP-1-S is a synthetic analog of glucagon-like peptide-1 (GLP-1), designed for use in academic and industrial research environments. This peptide is a critical tool for studying the mechanisms of GLP-1 receptor signaling, which has implications in metabolic regulation, neuroendocrine research, and potential drug discovery projects. GLP-1-S is provided in a research-grade formulation intended for controlled laboratory use only.

Research Context

Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose homeostasis, appetite regulation, and gastrointestinal motility. Naturally produced in the gut, GLP-1 binds to GLP-1 receptors to modulate insulin secretion, suppress glucagon release, and promote satiety. Synthetic analogs, such as GLP-1-S, offer enhanced stability and receptor affinity, enabling precise experimental manipulations in preclinical models.

Research Overview

GLP-1-S is utilized in basic science research to investigate the pharmacology of GLP-1 receptor agonists, including their effects on energy balance, neuroendocrine signaling, and metabolic diseases. Researchers employ this peptide to study receptor binding kinetics, pharmacokinetics, and potential therapeutic applications in conditions like diabetes or obesity. Given its role in counteracting insulin resistance, GLP-1-S serves as a valuable probe for exploring novel treatments in controlled experimental settings.

Key Research Focus Areas

  • Neuroendocrine Signaling: Investigating GLP-1’s role in hypothalamic and brainstem circuits, particularly in appetite regulation and metabolic feedback mechanisms.
  • Metabolic Pathways: Assessing GLP-1-S’s impact on glucose tolerance, insulin sensitivity, and adipocyte function in preclinical models.
  • Pharmacokinetics and Stability: Analyzing the peptide’s half-life, receptor binding affinity, and metabolic clearance to optimize analog design for therapeutic development.
  • Cross-Species Comparisons: Evaluating GLP-1-S’s efficacy in rodent, non-human primate, or other model systems to translate findings into potential clinical applications.

Research Compliance and Safety

This peptide is provided solely for research purposes under the supervision of qualified professionals in accredited institutions. Users must adhere to all applicable local, national, and international regulations governing research chemicals, including proper documentation, inventory control, and disposal protocols. GLP-1-S is not intended for human or animal therapeutic use and should not be administered outside a controlled experimental framework.

For research use only. Not for human or animal consumption.

Related Products

Age Verification!

*By continuing, you confirm eligibility and legal compliance.